Role of Mitochondrial Markers in Improved Detection and Risk-Stratification in Barrett's Esophagus Patients
Barrett's esophagus (BE) is the only known precursor of esophageal adenocarcinoma (EAC) and is amenable to treatment. However, more than 90 percent of EAC patients are never diagnosed with antecedent BE. Identification of molecular markers for BE is needed to improve detection of BE through efficient non-endoscopic methods that are cost-effective, sensitive and can be used to cater to a larger group of the population at risk. Alterations in mitochondria and mitochondrial DNA have been shown to be associated with various cancers, including esophageal cancer. Mitochondrial response to oxidative stress, alterations in mitochondrial metabolism, changes in mitochondrial membrane potential and mitochondrial genetic mutations have been found to be associated with BE pathogenesis. This mini-review focuses on the role of mitochondria in the pathogenesis of BE and EAC and the prospects of using that knowledge to develop effective strategies for the improved detection and risk-stratification in BE patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
The Yale journal of biology and medicine - 92(2019), 3 vom: 07. Sept., Seite 533-539 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grewal, Udhayvir S [VerfasserIn] |
|---|
| Themen: |
Barrett’s Esophagus |
|---|
| Anmerkungen: |
Date Completed 06.03.2020 Date Revised 09.03.2020 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM301516901 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301516901 | ||
| 003 | DE-627 | ||
| 005 | 20231225104808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1005.xml |
| 035 | |a (DE-627)NLM301516901 | ||
| 035 | |a (NLM)31543714 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grewal, Udhayvir S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Mitochondrial Markers in Improved Detection and Risk-Stratification in Barrett's Esophagus Patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Barrett's esophagus (BE) is the only known precursor of esophageal adenocarcinoma (EAC) and is amenable to treatment. However, more than 90 percent of EAC patients are never diagnosed with antecedent BE. Identification of molecular markers for BE is needed to improve detection of BE through efficient non-endoscopic methods that are cost-effective, sensitive and can be used to cater to a larger group of the population at risk. Alterations in mitochondria and mitochondrial DNA have been shown to be associated with various cancers, including esophageal cancer. Mitochondrial response to oxidative stress, alterations in mitochondrial metabolism, changes in mitochondrial membrane potential and mitochondrial genetic mutations have been found to be associated with BE pathogenesis. This mini-review focuses on the role of mitochondria in the pathogenesis of BE and EAC and the prospects of using that knowledge to develop effective strategies for the improved detection and risk-stratification in BE patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Barrett’s Esophagus | |
| 650 | 4 | |a Esophageal Adenocarcinoma | |
| 650 | 4 | |a Mitochondria | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Randhawa, Mehraj S |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Aryan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Yale journal of biology and medicine |d 1928 |g 92(2019), 3 vom: 07. Sept., Seite 533-539 |w (DE-627)NLM000296252 |x 1551-4056 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2019 |g number:3 |g day:07 |g month:09 |g pages:533-539 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2019 |e 3 |b 07 |c 09 |h 533-539 | ||